Latest research on Lantus

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.

Lantus dosage

Physicians would order insulin glargine (Lantus) vials and insulin Aspart (NovoLog) flexpens without specifying doses. [source, 2015]
Patients continued baseline treatment with Metformin (1-2 gm in divided doses) and MDI insulin (either premixed human 70/30 insulin twice daily or basal-bolus regimen with basal insulin glargine [rDNA origin; Lantus, Sanofi, Paris, France] and insulin Aspart [rDNA origin; Novolog, Novo Nordisk, Bagsvaerd, Denmark] at each meal). [source, 2015]
At the start of the observation period, patients were given insulin glargine (Lantus, Sanofi–Aventis, Shanghai, China) to be administered once daily via subcutaneous injection; dosing decisions and concomitant OAD therapy (dosage, type and changes where necessary) were at the discretion of the physician. [source, 2014]
Finally, a recent study (Add-on Lantus to Oral Hypoglycemic Agents [ALOHA] study) demonstrated that initiation of insulin glargine to achieve treatment target in Japanese type 2 diabetic patients (n = 3,180) on a basal-supported oral therapy (BOT) regimen is possible under real-life conditions using an appropriate starting dosage and subsequent dose adjustment (62). [source, 2013]
A German cohort study suggested a dose-response relation such that those taking higher doses of insulin glargine (Lantus) had an increased risk for cancer incidence compared with those prescribed human insulin and that both insulin glargine and human insulin were related to an increased risk of cancer incidence and mortality (4). [source, 2013]
We asked the subjects to dial up the insulin pen (Lantus Solo-Star Pen; Sanofi, Frankfurt, Germany) to a randomly selected dose between 30 and 40 units. [source, 2013]
To determine whether insulin levels in vivo can modulate liver lipid accumulation, we treated a group of hypoinsulinemic T1FLD mice with increasing doses of insulin (Lantus ™) for 12 hours. [source, 2012]
This international, multicenter, randomized, and open-label trial with a 2 × 2 factorial design evaluated the protective effects of n-3 PUFAs in a daily dose of 1 g versus corn oil, and Insulin Glargine (Lantus) versus standard care, on cardiovascular mortality and morbidity during 6 years of followup in 12 536 high-risk subjects with impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes. [source, 2012]
The average insulin dose remained unchanged for each patient throughout the duration of the study when compared with pretreatment/baseline even though the specific insulin formulation varied (Lantus long-acting insulin with multiple daily injections of Humalog, Humulin injectable or pump, or Novolog injectable). [source, 2011]
To eliminate possible confounding effects of STZ, insulin was immediately given using a long-term insulin preparation (Lantus Insulin glargine injection; sanofi-aventis Canada, Laval, Canada) at a dose of 5–15 units per mouse per day to maintain the blood glucose levels between 5–12 mmol/l when hyperglycemia was greater than 20 mmol/l on day 3 after STZ treatment in wild-type mice. [source, 2009]